Combining conventional therapy with immunotherapy: A risky business?

被引：26
作者：
Coosemans, A. [1 ,2 ]
Vankerckhoven, A. [2 ]
Baert, T. [2 ,3 ]
Boon, L. [4 ]
Ruts, H. [2 ]
Riva, M. [2 ]
Blagden, S. [5 ]
Delforge, M. [6 ]
Concin, N. [7 ]
Mirza, M. R. [8 ]
Ledermann, J. A. [9 ]
du Bois, A. [3 ]
Vergote, I [1 ,2 ,10 ]
机构：
[1] UZ Leuven, Dept Gynaecol & Obstet, Leuven Canc Inst, Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Tumour Immunol & Immunotherapy, Dept Oncol, ImmunOvar Res Grp, Leuven, Belgium
[3] KEM, Dept Gynaecol & Gynaecol Oncol, Essen, Germany
[4] Bioceros BV, Utrecht, Netherlands
[5] Univ Oxford, Early Phase Clin Trials Unit, Dept Oncol, Oxford, England
[6] UZ Leuven, Dept Haematol, Leuven Canc Inst, Leuven, Belgium
[7] Med Univ Innsbruck, Dept Gynaecol & Obstet, Innsbruck, Austria
[8] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[9] UCL, UCL Canc Inst, London, England
[10] Katholieke Univ Leuven, Lab Gynecol Oncol, Dept Oncol, Leuven, Belgium
来源：
EUROPEAN JOURNAL OF CANCER | 2019年 / 113卷
关键词：
Immunotherapy; Tumor immunology; Chemotherapy; Combination; Survival; TUMOR MICROENVIRONMENT; CHEMOTHERAPY; OVARIAN; CANCER; PROGRESSION;
D O I：
10.1016/j.ejca.2019.02.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码：41 / 44
页数：4
相关论文
共 18 条
  • [1] Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
    Alberts, David S.
    Marth, Christian
    Alvarez, Ronald D.
    Johnson, Gary
    Bidzinski, Mariusz
    Kardatzke, David R.
    Bradford, Williamson Z.
    Loutit, Jeff
    Kim, David H.
    Clouser, Mary C.
    Markman, Maurie
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 109 (02) : 174 - 181
  • [2] Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
    Auslander, Noam
    Zhang, Gao
    Lee, Joo Sang
    Frederick, Dennie T.
    Miao, Benchun
    Moll, Tabea
    Tian, Tian
    Wei, Zhi
    Madan, Sanna
    Sullivan, Ryan J.
    Boland, Genevieve
    Flaherty, Keith
    Herlyn, Meenhard
    Ruppin, Eytan
    [J]. NATURE MEDICINE, 2018, 24 (10) : 1545 - +
  • [3] The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer
    Baert, Thais
    Verschuere, Tina
    Van Hoylandt, Anais
    Gijsbers, Rik
    Vergote, Ignace
    Coosemans, An
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
  • [4] Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
    Brown, Jessica S.
    Sundar, Raghav
    Lopez, Juanita
    [J]. BRITISH JOURNAL OF CANCER, 2018, 118 (03) : 312 - 324
  • [5] Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
    Galluzzi, Lorenzo
    Buque, Aitziber
    Kepp, Oliver
    Zitvogel, Laurence
    Kroemer, Guido
    [J]. CANCER CELL, 2015, 28 (06) : 690 - 714
  • [6] Hallmarks of Cancer: The Next Generation
    Hanahan, Douglas
    Weinberg, Robert A.
    [J]. CELL, 2011, 144 (05) : 646 - 674
  • [7] Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
    Jiang, Peng
    Gu, Shengqing
    Pan, Deng
    Fu, Jingxin
    Sahu, Avinash
    Hu, Xihao
    Li, Ziyi
    Traugh, Nicole
    Bu, Xia
    Li, Bo
    Liu, Jun
    Freeman, Gordon J.
    Brown, Myles A.
    Wucherpfennig, Kai W.
    Liu, X. Shirley
    [J]. NATURE MEDICINE, 2018, 24 (10) : 1550 - +
  • [8] Immune Priming of the Tumor Microenvironment by Radiation
    Jiang, Wen
    Chan, Charles K.
    Weissman, Irving L.
    Kim, Betty Y. S.
    Hahn, Stephen M.
    [J]. TRENDS IN CANCER, 2016, 2 (11): : 638 - 645
  • [9] Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression
    Napoletano, Chiara
    Bellati, Filippo
    Landi, Rachele
    Pauselli, Simona
    Marchetti, Claudia
    Visconti, Valeria
    Sale, Patrizio
    Liberati, Marco
    Rughetti, Aurelia
    Frati, Luigi
    Panici, Pierluigi Benedetti
    Nuti, Marianna
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (12) : 2748 - 2759
  • [10] Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
    Park, Song Ee
    Lee, Se Hoon
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    Sun, Jong-Mu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (01) : 106 - 111
12